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ABSTRACT
ATM and ATR signaling pathways are well conserved throughout
evolution and are central to the maintenance of genome integrity.
Although the role of both ATM and ATR in DNA repair, cell cycle
regulation and apoptosis have been well studied, both still remain in
the focus of current research activities owing to their role in cancer.
Recent advances in the field suggest that these proteins have an
additional function in maintaining cellular homeostasis under both
stressed and non-stressed conditions. In this Cell Science at a
Glance article and the accompanying poster, we present an overview
of recent advances in ATR and ATM research with emphasis on that
into the modes of ATM and ATR activation, the different signaling
pathways they participate in – including those that do not involve DNA
damage – and highlight their relevance in cancer.
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Introduction
Ataxia-telangiectasia-mutated (ATM) and ataxia telangiectasia and
Rad3-related (ATR) proteins are key regulators of the DNA damage
response (DDR), and maintain genome integrity in eukaryotic cells.
ATM and ATR are expressed in most tissues, and mutations in the
encoding genes result in the autosomal recessive disorders ataxia
telangiectasia (Lavin, 2008) and Seckel syndrome (O’Driscoll et al.,
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2003), respectively. The clinical manifestations of ataxia
telangiectasia include progressive ataxia, telangiectasia, immune
defects, genome instability and malignancy; Seckel syndrome is
characterized by postnatal dwarfism, microcephaly, intrauterine
growth defects and mental retardation. Savitsky and co-workers
first described ATM as the gene responsible for ataxia telangiectasia
(Savitsky et al., 1995), whereas ATR was first identified and cloned
from human T cells (Cimprich et al., 1996). ATM and ATR belong to
the class-IV phosphoinositide 3-kinase (PI3K)-related kinase (PIKK)
family, along with mammalian target of rapamycin (mTOR) and
DNA-dependent protein kinase (DNA-PK). ATM and ATR
nonetheless lack lipid kinase activity; instead, they phosphorylate
proteins that contain Ser or Thr residues that are followed by Gln (SQ
or TQ motifs) (Bakkenist and Kastan, 2004). DDR is mediated by
ATM and ATR, as well as by two downstream kinases, checkpoint
kinases 1 and 2 (Chk1 and Chk2; encoded by CHEK1 and CHEK2,
respectively). After their activation, both ATM and ATR upregulate
cell cycle checkpoint pathways, inducing cell cycle arrest and DNA
repair. ATM and ATR respond to different types of DNA lesions, to
which they are recruited through specific co-factors; ATM responds
primarily to DNA double-strand breaks (DSBs) (Paull, 2015),
whereas ATR protects the integrity of replicating chromosomes
(Branzei and Foiani, 2008). ATR is also activated byDSBs, however,
through a mechanism that depends on ATM and the MRE11–
RAD50–NBS1 (MRN) complex (Doksani et al., 2009; Jazayeri et al.,
2006). As will be discussed below, recent studies suggest that ATM
and ATR also act in response to other cellular stresses, and that they
might control cell pathways that do not converge on DNA repair
mechanisms but that instead maintain cell homeostasis.
ATM and ATR are members of the PIKK family
ATM and ATR belong to the PIKK family together with mTOR,
human suppressor of morphogenesis in genitalia-1 (SMG-1),
DNA-PK catalytic subunit (DNAPKcs; encoded by PRKDC), and
transformation/transcription-associated protein (TRRAP) (Lovejoy
and Cortez, 2009). PIKK-family members share similarity in their
kinase domains with the catalytic loops of class-I PI3K and are
therefore categorized separately from the classic protein kinases. In
addition, PIKK enzymes have a conserved FRAP-ATM-TRRAP
(FAT), PIKK-regulatory domain (PRD) and FAT carboxy-terminal
(FATC) domains, as well as an N-terminus that bears numerous
α-helical Huntingtin, elongation factor 3, protein phosphatase 2A,
TOR1 (HEAT) repeat motifs (Lovejoy and Cortez, 2009). The FAT
domain is at theN-terminus of the kinase domain, whereas the FATC
domain lies in its C-terminus (see poster). The PRD, FAT and FATC
regions are crucial for ATR and ATM activation, and mutations in
these regions can hamper their kinase activity (Bakkenist and
Kastan, 2003; Liu et al., 2011; Mordes and Cortez, 2008; Nam and
Cortez, 2011; Sun et al., 2005). The N-terminal HEAT repeats act as
a scaffold; they mediate the interactions of ATM and ATR with
proteins that regulate their catalytic activity and have an important
role in their stability (see poster) (Perry and Kleckner, 2003). The
HEAT repeats can also act as elastic connectors that undergo
deformation following mechanical stimulation and regulate protein
activity (Grinthal et al., 2010). As is the case for other PI3K-family
members, PIKKs exist as homo- or heterodimers, and dimerization
influences their stability and kinase activity. Accordingly, ATM
forms dimers or oligomers under non-stress conditions and it is
released in monomeric form following induction of stress
(Bakkenist and Kastan, 2003). ATR forms a heterodimer with its
obligatory partner ATR-interacting protein (ATRIP) (Cortez et al.,
2001); this heterodimerization stabilizes ATR, although the
interaction with ATRIP does not appear to be very strong (Unsal-
Kacmaz and Sancar, 2004).
ATR activation
ATR is activated in response to a variety of DNA lesions that
induce the formation of single-strand (ss)DNA (Cimprich and
Cortez, 2008; Zou and Elledge, 2003). ATR activation is a multi-
step process, because the ATR–ATRIP heterodimer is unable to
interact with DNA directly, and depends on nucleofilaments that
are formed between the replication protein A heterotrimer (RPA)
and ssDNA for DNA binding (Zou and Elledge, 2003). ATR-
associated ATRIP interacts directly with ssDNA-bound RPA and
so promotes ATR localization to sites of replication stress and
DNA damage (Zou and Elledge, 2003) (see poster). It has recently
been suggested that pre-mRNA processing factor 19 (PRP19)-
assisted ubiquitylation of RPA facilitates ATRIP binding to
damaged DNA (Maréchal et al., 2014), which leads to partial ATR
activation (Ashton et al., 2013). The RPA-assisted ATRIP–ATR
complex then interacts with the DNA-damage-specific RAD9–
RAD1–HUS1 clamp (also called 9-1-1) that is bound at junctions
between ssDNA and double-strand (ds)DNA (Ellison and
Stillman, 2003). 9-1-1 itself is loaded onto the ssDNA–dsDNA
junction by the clamp loader complex, RAD17–RFC, which is
facilitated by RPA (Ellison and Stillman, 2003; Zou et al., 2003).
This is followed by phosphorylation of the 9-1-1 subunit RAD9
on residue S387, which enables the association of DNA
topoisomerase 2-binding protein 1 (TopBP1) with the FATC
domain of ATR (St. Onge et al., 2003), leading to ATR activation
(Choi et al., 2010) (see poster). Furthermore, TopBP1 can interact
with both phosphorylated or unphosphorylated 9-1-1 complexes
(Delacroix et al., 2007; Lee and Dunphy, 2010; Lee et al., 2007),
and, moreover, its interaction with 9-1-1 can be mediated by other
proteins such as RHINO (Rad9, Rad1, Hus1 interacting nuclear
orphan, encoded by RHNO1) (Cotta-Ramusino et al., 2011).
A recent study has confirmed the function of RHINO in ATR
activation following genotoxic stress, but also showed that RHINO
is dispensable for the interaction of TopBP1 with the 9-1-1
complex (Lindsey-Boltz et al., 2015) (see poster). Importantly,
the ATR-activation domain in TopBP1 can also mediate ATR
activation in the absence of DNA damage or other known ATR
activators, and so can initiate checkpoint signaling in the absence
of DNA damage (Toledo et al., 2008). Although the current notion
is that ATR is activated by RPA–ssDNA nucleofilaments, some
studies appear to contradict this model because they have found
RPA to be dispensable for ATR activation and subsequent Chk1
phosphorylation following genotoxic stress (Ball et al., 2005;
Dodson et al., 2004). Moreover, the phenotypes of cells that have
been depleted of RAD9 and of HUS1-depleted cells do not fully
recapitulate those of cells with defective ATR signaling (Hopkins
et al., 2004; Weiss et al., 2000), suggesting that RAD9 and HUS1
might be redundant for some of the ATR functions, or that ATR
has other functions that do not require the 9-1-1 complex.
ATM activation
The mechanisms of ATM activation after DSB formation have
recently been reviewed elsewhere (Paull, 2015). ATM activation
comprises mainly the formation of ATM monomers and activation
of the MRN–ATM signaling axis, as discussed below. How exactly
DSBs recruit activators of ATM that induce its binding to DSBs,
nonetheless, remains unclear.
Under non-stress conditions, ATM is inactive and exists in the
form of a multimer (a dimer or higher order multimer) (Bakkenist
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and Kastan, 2003); like other PI3Ks, it requires a stimulus for
activation. In human cells, following DNA damage, ATM
undergoes autophosphorylation at residue S1981 in its FAT
domain, which results in the simultaneous dissociation of the
ATM homodimers (Bakkenist and Kastan, 2003) (see poster). An
S1981A mutation renders ATM a dominant-negative protein,
triggering DDR in response to DSB formation, which highlights
the importance of autophosphorylation-mediated monomerization
for ATM function (see poster). Phosphorylation of S1981 also
stabilizes ATM at damaged DNA regions (So et al., 2009).
Autophosphorylation of ATM at residues S367 and S1893 also
contributes to its activation (Kozlov et al., 2006), although
mutagenesis of the corresponding residues S367, S1899 and
S1987 in murine ATM has no impact on ATM activation
following induction of DNA damage in vivo (Daniel et al., 2008).
In Xenopus extracts, ATM autophosphorylation is not involved in
MRN-mediated ATM monomerization, ATM activation and its
recruitment to DSBs (Lee and Paull, 2005). Taken together, these
findings suggest that although ATM monomerization is essential
for its functional activation, the role of autophosphorylation in
activation might not be conserved across species. Among other
ATM-activating steps, the acetylation of ATM at K3016 appears to
be essential for its autophosphorylation and monomerization
following DNA damage (Sun et al., 2005, 2007). This is
mediated by the association of the histone acetyltransferase KAT5
with histone H3 trimethylated at Lys9 (H3K9me3), which is
induced when KAT5 is phosphorylated by the kinase cellular (c)-
Abl (Kaidi and Jackson, 2013).
TheMRN complex binds to dsDNA ends and provides a platform
for ATM recruitment, which suggests that the MRN complex acts
a sensor that initiates ATM activation (Lee and Paull, 2005). It
has been proposed that ATM is stimulated by the MRN complex
through its exo- and endonuclease activity, DNA tethering
capability and conformational changes in the MRN complex that
occur after DNA binding (Carson et al., 2003; Dupré et al., 2006;
Lee and Paull, 2004; You et al., 2005). In addition, the interaction
of ATM with the MRN component NBS1 (also known NBN) as is
crucial for its recruitment to DSBs (Falck et al., 2005). Recent
observations also suggest that the nuclease activity of MRE11 in the
MRN complex is dispensable for ATM activation; instead, the
coiled-coil domain and zinc hook in RAD50, and the ATP-driven
conformational changes in the MRN complex that help to position
the MRN complex in its functional conformation assist ATM
activation by participating in DNA binding (Lee et al., 2013).
Recent work has demonstrated that in the absence of Ku (encoded
by XRCC6), the MRN complex is dispensable for ATM activation
and its recruitment to DSBs, and for G2/M checkpoint activation
following DNA damage (Hartlerode et al., 2015); however, the
MRN complex remains to be vital for the ATM-dependent DDR
(Hartlerode et al., 2015). Nonetheless, the exact mechanisms
through which MRN activates ATM in a DSB-dependent manner
remain to be elucidated. Dephosphorylation of ATM by the protein
phosphatases PP2A (Goodarzi et al., 2004), PP1 (Peng et al., 2010),
Wip1 (also known as PPM1D) (Shreeram et al., 2006) and PP5 (Ali
et al., 2004) might also be relevant for its activation.
Signaling outputs of ATR and ATM
Phosphorylation of downstream-acting proteins is at the heart of
ATR and ATM signaling in response to cell stress events. Both
kinases phosphorylate proteins on S/TQ motifs (Kim et al., 1999)
and initiate widespread cell responses through phosphorylation of
downstream effector proteins. Much of the knowledge gained with
regard to ATR and ATM signaling cascades has been derived
from the treatment of various cell types with high doses of
DNA-damaging agents, which result in a burst of ATR and ATM
activity, and downstream signaling. These studies might,
nonetheless, underestimate the impact of ATR- and ATM-
mediated phosphorylation events that are elicited under more
physiological conditions, particularly in light of the accumulating
evidence that suggests that ATM- and ATR-mediated pathways are
not restricted to nuclear events and DDR (see poster). Screens for
S/TQ-containing substrates of ATR and ATM following DNA
damage have also revealed putative substrates outside of the
nucleus, as well as factors that are not directly linked to DNA repair
processes (Matsuoka et al., 2007; Mu et al., 2007; Paulsen et al.,
2009), although the functional relevance of many of these
phosphorylation events remains to be determined. Intriguingly,
DNA-PK has also been located at the Golgi, reinforcing the
possibility that other PIKKs might also function outside of the
nucleus (Farber-Katz et al., 2014).
In the following sections, we will discuss ATR and ATM
signaling pathways in response to genotoxic stress, as well as in
other cell-stress conditions, and outline how targeting of ATR and
ATM could be employed for cancer therapy.
ATR in replication stress
Activation of the ATR–ATRIP complex (which is loaded onto DNA
together with TopBP1) initiates a signaling cascade that coordinates
cell cycle progression with DNAmetabolic processes. ATR activity
is necessary both for the stabilization of stalled replication forks and
for fork restart following replication stress. On one hand, ATR
inhibition results in the increased firing of origins in the absence of
DNA damage (Shechter et al., 2004), but on the other hand, under
replication stress, ATR-dependent phosphorylation of ‘Fanconi
anemia, complementation group I’ (FANC1) inhibits the firing of
dormant origins (Chen et al., 2015b). In addition, ATR deficiency in
aphidicholine-treated cells causes incomplete replication of regions
with fragile sites (Casper et al., 2002; Paulsen and Cimprich, 2007).
When a replication fork encounters a gene that is being transcribed,
the Mec1/ATR pathway phosphorylates nucleoporin components to
release the transcribed chromatin, which is attached to the nuclear
envelope (Bermejo et al., 2011), thereby preventing torsional-stress-
induced fork reversal. Hence, the ATR response ensures robust
replication through different means – by stabilizing replication forks
(Paulsen and Cimprich, 2007), preventing fragile-site expression
(Casper et al., 2002; Cha and Kleckner, 2002), influencing
replication origin firing (Chen et al., 2015b; Shechter et al., 2004)
and also coordinating replication with transcription (Bermejo et al.,
2011), as well as by triggering the replication stress response (Flynn
and Zou, 2011) (see poster). Under conditions of replication stress,
a balance between the amounts of RPA and ssDNA appears to be
crucial for the stability of the replication fork (Toledo et al., 2013).
Accordingly, ssDNA uncoating owing to RPA paucity results in
collapse of the replication fork and the generation of DSBs (Toledo
et al., 2013).
ATR in cell cycle regulation
ATR also influences DNA repair processes, such as the repair of
DSBs, nucleotide excision repair (NER) and inter-strand crosslink
repair (ICL) (reviewed in Cimprich and Cortez, 2008). The best-
characterized ATR effector, to date, is Chk1 (Zhao and Piwnica-
Worms, 2001), which is activated through ATR-mediated
phosphorylation at residues S317 and S345 (Liu et al., 2000) in a
reaction that is stimulated by claspin binding to Chk1 (Lindsey-
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Boltz et al., 2009), by the 9-1-1 complex (Liu et al., 2012; Wang
et al., 2006) and RHINO (Lindsey-Boltz et al., 2015), as well as by
other factors (Nam and Cortez, 2011) (see poster). Chk1 activation
stabilizes the chromatin-bound CDC7–DBF4 apoptosis signal-
regulating kinase (ASK) complex, which assists in replication and
origin firing (Yamada et al., 2013). Chk1 affects progression
through S phase at the level of origin firing, replication elongation
and fork integrity (Brown and Baltimore, 2003; Heffernan et al.,
2007; Petermann et al., 2006, 2010; Segurado and Diffley, 2008;
Zhao et al., 2002). In addition, activated Chk1 also has an effect on
S-phase progression through phosphorylation of CDC25 and
regulation of cyclin-dependent kinases (CDKs) (Sanchez et al.,
1997). The ATR-mediated Chk1 pathway also has a central role in
preventing cells from entering into mitosis with unreplicated or
damaged DNA (Brown and Baltimore, 2003). Chk1-dependent
sequestration of CDC25C into the cytoplasm and degradation of
CDC25A maintains CDK1 in its inactive state, resulting in G2/M
arrest (Mailand et al., 2002; Nghiem et al., 2001; Peng et al., 1997;
Sanchez et al., 1997).
Cells that express kinase-dead ATR mutants undergo premature
chromosome condensation and entry into mitosis (Nghiem et al.,
2001). Other ATR targets, such as the helicase SMARCAL1, whose
fork regression activity is compromised after phosphorylation by
ATR, thereby preventing aberrant fork processing, thus have
important roles in the response of ATR to replication stress
(Couch et al., 2013). ATR is also activated in G1 following γ-
irradiation in order to facilitate DNA repair (Gamper et al., 2013). It
has also been suggested that ATR has a role in the physical
separation of cells during cytokinesis through Chk1-mediated
phosphorylation of Aurora B (encoded by AURKB) (Mackay and
Ullman, 2015) (see poster), a known mediator of furrow cleavage
that promotes cytokinesis (Marumoto et al., 2005). We have
recently shown that ATR responds to osmotic andmechanical stress,
and that cells derived from individuals with Seckel syndrome fail to
coordinate chromatin condensation with nuclear envelope
breakdown (Kumar et al., 2014) (see poster). This process does
not appear to involve DNA-damage sensing and might be mediated
through the elastic properties of the N-terminal ATR HEAT repeats,
which could act as mechanosensors (Grinthal et al., 2010).
However, more work is required to elucidate the mechanism of
ATR activation in response to mechanical stress.
Cellular effects of ATM signaling
ATM activation has a pivotal position in DDR, and is triggered in
response to oxidative stress (Okuno et al., 2012) and DSB formation
(Lee and Paull, 2005; van Gent et al., 2001). A recent report has also
suggested that a very early ATM activation event in response to
replication stress – the sensing of regressed replication forks – is
triggered by the FBH1 (encoded by FBXO18) helicase (Fugger
et al., 2015). After its activation, ATM induces a wide spectrum of
signal transduction pathways that connect processes involved in
DNA repair, cell metabolism, bioenergetics, as well as protein
translation and transcription. The best-characterized effector of
ATM signaling is Chk2, which is phosphorylated at residue T62 by
ATM following DSB formation (Chaturvedi et al., 1999; Matsuoka
et al., 1998, 2000). In addition to Chk2, ATM-dependent DSB
repair also involves direct phosphorylation of MRE11, RAD9,
RAD50, p53, NBS1, DNA-PKs, CtIP (encoded by RBBP8) and
many other proteins, as recently reviewed elsewhere (Shiloh and
Ziv, 2013). ATM-mediated pathways have also been shown to be
involved in chromatin relaxation (Goodarzi et al., 2008; Moyal
et al., 2011; Polo et al., 2010; Ziv et al., 2006), nucleosome
remodeling (Goodarzi et al., 2011), and activation of p53, NF-κB
and microRNAs (Turenne et al., 2001; Wu et al., 2006; Zhang et al.,
2011) in order to regulate the transcription of genes that are needed
to modulate cell responses following DNA damage (see poster).
Box 1. Relevance of ATM and ATR signaling in cancer
Both ATM and ATR signaling impact on tumorigenesis; in fact, in the
early phases of tumorigenesis, both ATM and ATR provide a barrier to
tumor progression by inducing cell cycle arrest and apoptosis (Bartek
et al., 2007; Bartkova et al., 2006; Halazonetis et al., 2008; Pusapati
et al., 2006). In pre-cancerous lesions, both the ATM and ATR pathways
are activated, thereby helping the cell to mount a resistance to tumor
development (Gorgoulis et al., 2005; Negrini et al., 2010). In addition,
loss-of-function mutations or deletions of ATM or ATR, as well as their
reduced kinase activity or expression levels, or deletions of components
of their downstream pathways, all promote cell survival and result in a
multi-fold increase in the propensity of a cell to become cancerous, and in
an acceleration of tumor progression (Nevanlinna and Bartek, 2006;
Spring et al., 2002; Vahteristo et al., 2002; Bertoni et al., 1999;
Greenman et al., 2007; Guarini et al., 2012; Hollestelle et al., 2010;
Menoyo et al., 2001; Reiman et al., 2011; Renwick et al., 2006; Roberts
et al., 2012; Squatrito et al., 2010; Tanaka et al., 2012; Zighelboim et al.,
2015, 2009) (see poster). In particular, in ATM, distinct mutations have
been found that cause different human malignancies, including lung
cancer, breast cancer, colon cancer, lymphocytic leukemia, pancreatic
cancer, and head and neck cancer, among others (Ding et al., 2008;
Goldgar et al., 2011; Guarini et al., 2012; Roberts et al., 2012; Seshagiri
et al., 2012) (see poster). Homozygous loss-of-function mutations or
deletion of ATR or Chk1 have not yet been reported; however, there are
sporadic studies that show mutations in ATR or Chk1 in certain cancer
types (Kim et al., 2007; Lewis et al., 2007; Liu et al., 2008; Menoyo et al.,
2001; Zighelboim et al., 2009) (see poster), suggesting that the ATR–
Chk1 axis cannot be generalized as a canonical tumor suppressor
pathway.
Although the current view in the field is that ATM and ATR signaling
inhibits tumor progression rather than promoting cancer (Bartkova et al.,
2006; Gorgoulis et al., 2005; Halazonetis et al., 2008), there has been
a number of recent reports of overexpression of ATM or ATR, or of
activation of the downstream pathways in different cancers (Albiges
et al., 2014; Bhatia et al., 2013; Hoglund et al., 2011; Mahajan et al.,
2012; Sarmento et al., 2015; Tho et al., 2012; Vadnais et al., 2012;
Verlinden et al., 2007; Xu et al., 2013) (see poster). Of note, the addition
of an extra allele of Chk1 has even been found to promote Ras- or
E1A-mediated transformation more efficiently in comparison to such
transformation of wild-type littermates (Lopez-Contreras et al., 2012),
suggesting that the ATR–Chk1 axis has a pro-malignant transformation
role.
Box 2. ATR and ATM as targets for cancer therapy
Considering their roles as tumor suppressors as well as facilitators in
mediating responses to DNA damage, ATM and ATR have long been
considered as potential drug targets for cancer therapy; however, the
generation of specific inhibitors for ATM and ATR has remained a difficult
task. The compounds that have initially been used to inhibit ATM and
ATR are the pan-PI3K inhibitors LY294002, caffeine (Sarkaria et al.,
1999) and wortmannin (Sarkaria et al., 1998). Recently, more specific
compounds have been identified (Batey et al., 2013; Fokas et al., 2012;
Guo et al., 2014; Toledo et al., 2011). ATM-specific inhibitors identified
to date include CP-466722, KU-55933, KU-60019 and KU-559403,
whereas the ATR-specific inhibitors are schisandrin B, VE-821, VE-822,
AZ20 and AZD6738. A combination of ATM or ATR inhibitors, with
chemotherapeutic drugs or radiotherapy has been highly successful in
the treatment of many types of cancer. A recent review provides a
detailed update on ATM and ATR inhibitors, and their potential as drug
targets (Weber et al., 2014).
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Another recent report shows that R-loop-mediated ATM activation
regulates the expression of target genes and accelerates alternative
pre-mRNA splicing in a genome-wide manner to produce new gene
products following irradiation with ultraviolet C (UVC) (Tresini
et al., 2015).
ATM also mediates nuclear and cytoplasmic signaling cascades
that are unrelated to DNA repair events but are instead involved in
maintaining cell homeostasis, such as insulin signaling (Yang and
Kastan, 2000), as well as in responses to hyperthermia (Hunt et al.,
2007), hypoxia (Bencokova et al., 2009) and hypotonic stress
(Bakkenist and Kastan, 2003; Kanu and Behrens, 2007). ATM is
also activated in the absence of DNA damage upon mitotic spindle
checkpoint activation (Yang et al., 2011) and during hematopoietic
stem cell survival (Ito et al., 2004; Maryanovich et al., 2012). ATM
activation in response to reactive oxygen species (ROS) is
independent of the MRN complex (Guo et al., 2010) and involves
ATM-interacting protein (ATMIN) (Kanu and Behrens, 2007),
suggesting that the NBS1 subunit in the MRN complex and ATMIN
respond to distinct stimuli (Zhang et al., 2012). ROS-mediated
ATM signaling represses mTORC1 signaling and, therefore, cell
growth and proliferation through activation of TSC2 (a negative
regulator of mTOR) by liver kinase B1 (LKB1, also known as
STK11) and AMP-dependent protein kinases (AMPKs) (Alexander
et al., 2010) (see poster).
ATM activation also affects mitochondrial physiology and
function by helping to eliminate defective mitochondria through
mitophagy, thus providing a link between ROS metabolism and
mitochondrial dysfunction (Valentin-Vega et al., 2012). In
accordance with this, fibroblasts from individuals with ataxia
telangiectasia have higher ROS levels and are sensitive to oxidative
stress (Ito et al., 2004; Reichenbach et al., 2002), which suggests that
ATM not only protects cells from oxidative damage but that it also
maintains low endogenous ROS levels. Interestingly, ROS-induced
ATM activation has been reported to assist in cell migration and
invasion through interleukin 8 (IL-8), suggesting that ATM might
also function to promote tumor progression (Chen et al., 2015a).
Although there is emerging evidence for a role of ATM in promoting
tumorigenesis, early in tumorigenesis, ATM signaling provides a
barrier to activated oncogenes and tumor progression, rather than
promoting cancer (Bartkova et al., 2005; Gorgoulis et al., 2005;
Halazonetis et al., 2008) (see Box 1), and ATM has been one of the
prime drug targets for cancer therapy (see Box 2). Under hypoxia,
increased replication stress and H3K9me3 levels, together with
repressed PP2A activity, facilitate ATM activation and prevent DSB
formation, thereby enabling normal replication (Olcina et al., 2013).
Activated ATM also phosphorylates and activates the transcriptional
regulator hypoxia-inducible factor 1α (HIF1α), resulting in the
upregulation of REDD1, a TSC2 activator; this leads to suppression
of mTORC1 signaling and results in a decrease of anabolic processes
and an increase in catabolic processes (Cam et al., 2010).
Conclusions
ATM and ATR kinases have been extensively studied with respect
to roles in the DDR; here, key cofactors mediate their recruitment to
DNA damage sites and contribute to the activation of DDR
signaling. Recent findings suggest that both ATM and ATR have
additional functions in maintaining cell homeostasis that are
unrelated to the DNA-damage cascade. Further exploring the
ATM- and ATR-mediated pathways that function in response to
distinct stress conditions will help us to not only better understand
the connections between ATR, ATM and mTOR signaling, but also
to rationalize the use of ATR and ATM inhibitors in cancer therapy.
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Dupré, A., Boyer-Chatenet, L. and Gautier, J. (2006). Two-step activation of ATM
by DNA and the Mre11–Rad50–Nbs1 complex. Nat. Struct. Mol. Biol. 13,
451-457.
Ellison, V. and Stillman, B. (2003). Biochemical characterization of DNA damage
checkpoint complexes: clamp loader and clamp complexes with specificity for 5′
recessed DNA. PLoS Biol. 1, e3.
Falck, J., Coates, J. and Jackson, S. P. (2005). Conservedmodes of recruitment of
ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 434, 605-611.
Farber-Katz, S. E., Dippold, H. C., Buschman, M. D., Peterman, M. C., Xing, M.,
Noakes, C. J., Tat, J., Ng, M. M., Rahajeng, J., Cowan, D. M. et al. (2014). DNA
damage triggers Golgi dispersal via DNA-PK and GOLPH3. Cell 156, 413-427.
Flynn, R. L. and Zou, L. (2011). ATR: a master conductor of cellular responses to
DNA replication stress. Trends Biochem. Sci. 36, 133-140.
Fokas, E., Prevo, R., Pollard, J. R., Reaper, P. M., Charlton, P. A., Cornelissen,
B., Vallis, K. A., Hammond, E. M., Olcina, M. M., Gillies McKenna, W. et al.
(2012). Targeting ATR in vivo using the novel inhibitor VE-822 results in selective
sensitization of pancreatic tumors to radiation. Cell Death Dis. 3, e441.
Fugger, K., Mistrik, M., Neelsen, K. J., Yao, Q., Zellweger, R., Kousholt, A. N.,
Haahr, P., Chu, W. K., Bartek, J., Lopes, M. et al. (2015). FBH1 catalyzes
regression of stalled replication forks. Cell Rep. 10, 749-1757.
Gamper, A. M., Rofougaran, R., Watkins, S. C., Greenberger, J. S., Beumer,
J. H. and Bakkenist, C. J. (2013). ATR kinase activation in G1 phase facilitates
the repair of ionizing radiation-induced DNA damage. Nucleic Acids Res. 41,
10334-10344.
Goldgar, D. E., Healey, S., Dowty, J. G., Da Silva, L., Chen, X., Spurdle, A. B.,
Terry, M. B., Daly, M. J., Buys, S. M., Southey, M. C. et al. (2011). Rare variants
in the ATM gene and risk of breast cancer. Breast Cancer Res. 13, R73.
Goodarzi, A. A., Jonnalagadda, J. C., Douglas, P., Young, D., Ye, R., Moorhead,
G. B. G., Lees-Miller, S. P. and Khanna, K. K. (2004). Autophosphorylation of
ataxia-telangiectasia mutated is regulated by protein phosphatase 2A. EMBO J.
23, 4451-4461.
Goodarzi, A. A., Noon, A. T., Deckbar, D., Ziv, Y., Shiloh, Y., Löbrich, M. and
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Liu, S., Shiotani, B., Lahiri, M., Maréchal, A., Tse, A., Leung, C. C. Y., Glover,
J. N. M., Yang, X. H. and Zou, L. (2011). ATR autophosphorylation as amolecular
switch for checkpoint activation. Mol. Cell 43, 192-202.
Liu, S., Song, N. and Zou, L. (2012). The conserved C terminus of Claspin interacts
with Rad9 and promotes rapid activation of Chk1. Cell Cycle 11, 2711-2716.
Lopez-Contreras, A. J., Gutierrez-Martinez, P., Specks, J., Rodrigo-Perez, S.
and Fernandez-Capetillo, O. (2012). An extra allele of Chk1 limits oncogene-
induced replicative stress and promotes transformation. J. Exp. Med. 209,
455-461.
Lovejoy, C. A. and Cortez, D. (2009). Common mechanisms of PIKK regulation.
DNA Repair 8, 1004-1008.
Mackay, D. R. and Ullman, K. S. (2015). ATR and a Chk1-Aurora B pathway
coordinate postmitotic genome surveillance with cytokinetic abscission.Mol. Biol.
Cell 26, 2217-2226.
Mahajan, K., Coppola, D., Rawal, B., Chen, Y. A., Lawrence, H. R., Engelman,
R. W., Lawrence, N. J. and Mahajan, N. P. (2012). Ack1-mediated androgen
receptor phosphorylation modulates radiation resistance in castration-resistant
prostate cancer. J. Biol. Chem. 287, 22112-22122.
Mailand, N., Podtelejnikov, A. V., Groth, A., Mann, M., Bartek, J. and Lukas, J.
(2002). Regulation of G2/M events by Cdc25A through phosphorylation-
dependent modulation of its stability. EMBO J. 21, 5911-5920.
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